Table 4.

Hyponatremic overcorrection status and treatment during the first 24 hours by SHOR score

SHOR ScoreNo. of Patients (N=623)Hyponatremic OvercorrectionaIV Fluids (L)IV Sodium (mEq)Desmopressin Given,
No, n=449 (72%)Unlikely, n=25 (4%)Possible, n=64 (10%)Definite, n=85 (14%)Mean (95% CI)Median (IQR)Mean (95% CI)Median (IQR)n (%)
<−39894 (96%)3 (3%)1 (1%)0 (0%)0.6 (0.5 to 0.8)0.3 (0–1.0)95.4 (71.3 to 119.5)47.3 (0–154.0)0 (0%)
−3 to −1167141 (84%)5 (3%)12 (7%)9 (5%)1.1 (1.0 to 1.3)1.0 (0.3–1.6)176.3 (151.8 to 200.7)154 (45.7–261.8)0 (0%)
0–2191138 (72%)10 (5%)25 (13%)18 (9%)1.3 (1.2 to 1.5)1.2 (0.5–2.0)206.3 (180.9 to 231.6)188.6 (74.4–308)2 (1%)
3–410760 (56%)4 (4%)18 (17%)25 (29%)1.5 (1.2 to 1.7)1.2 (0.6–2.1)219.0 (185.2 to 252.8)175.2 (100.1–326)6 (6%)
5+6016 (27%)3 (5%)8 (13%)33 (55%)1.8 (1.4 to 2.1)1.6 (0.9–2.8)262.7 (216.5 to 309.0)232.7 (128.5–398.8)1 (2%)
  • The total volume of fluids and amount of sodium given intravenously during the first 24 hours after the baseline sodium measurement was determined. The SHOR score was strongly associated with hyponatremic overcorrection class (chi-squared value 156.8; P<0.001; Spearman correlation 0.45; 95% CI, 0.36 to 0.49). SHOR, Severe Hyponatremia Overcorrection Risk; 95% CI, IV, intravenous; 95% confidence interval; IQR, interquartile range.

  • a These values are on the basis the hyponatremic overcorrection category having the highest probability (Supplemental Table 5) for each patient and is the average of 1000 bootstrap samples to account for correlated hyponatremic overcorrection criteria (Supplemental Table 2).